Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KiOslim is a consumer health ingredient and dietary supplement developed by Kitozyme, a Belgian biotechnology company. It is a proprietary blend of natural, non-GMO, non-animal fibers derived from fungal chitosan, specifically sourced from *Aspergillus niger*. Marketed as a natural fat binder for weight management, KiOslim works through a physical mechanism in the digestive tract, where it can bind up to 42% of dietary fats and reduce sugar absorption by approximately 46%. By decreasing the absorption of these macronutrients, it helps to reduce overall calorie intake and manage body weight. Additionally, KiOslim supports the regulation of blood sugar and cholesterol levels. It is a vegan, non-allergenic specialty chemical ingredient used in various consumer health formulations rather than a pharmaceutical drug with a specific molecular target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on KiOslim.